More biotechnology companies are going public in Europe. Last year, 15 firms went public on the continent’s 15 most important stock exchanges, up from 5 in 2013. These companies raised an average of €48 million ($64 million), a 303.4% increase from the average amount raised in 2013. In total, the new listings raised €719.8 million. […]
The Chinese government has outlined plans to promote innovation and streamline administration of science and technology programs. According to Zhao Lu of the Ministry of Finance, the plan would affect more than 90 programs with total funding of more than $13.1 billion. The programs are now administered by over 40 government bodies, according to the […]
In 2013, R&D spending in Spain totaled €13,012 million ($17,349 million), down 2.8%. R&D accounted for 1.2% of GDP, a drop of three-hundredths of a percentage point. The business sector performed 53% of R&D. Higher education, public administration and private nonprofits performed 28%, 19% and less than 1%, respectively. Business, higher education and public administration […]
A December 2014 survey of 704 senior executives based in Asia found that they expect higher revenue growth for their firms in 2015 in Asia (including Australia and New Zealand). The fastest growth is expected in China, Southeast Asia and India, at 10.1%, 9.3% and 8.8%, respectively. For the chemical industry, the highest expected rates […]
The UK’s science and innovation strategy was released this month, reflecting the government’s long-term commitment to science despite challenging economic times. Included in the strategy are plans for funding for scientific infrastructure and research, and for spurring innovation. Capital funding for science will receive £5.9 billion ($9.3 billion) from fiscal 2016 through fiscal 2021, with […]
Gross expenditure on R&D (GERD) in South Africa rose 7.5% in fiscal 2013 to ZAR 23.9 billion ($2.2 billion). At 0.76%, GERD as a percentage of GDP did not change. Expenditures rose in all sectors, with business and higher education leading spending at ZAR 10.6 billion ($957 million) and ZAR 7.3 billion ($664 million), up […]
A survey of 186 EU-based companies, which together in 2013 invested €60 billion ($80 billion) in R&D, showed that the firms expect R&D investment to grow on average 4.2% annually from 2014 to 2016. The highest expected increases in spending are by aerospace and defense, health care equipment and services, and fixed-line telecommunication firms, with […]
Chancellor George Osborne has allotted £5.9 billion ($9.2 billion), £1.1 billion per year, over the next parliamentary term to research infrastructure. Half of the £3 billion for supporting labs will be awarded based on competition. “Grand challenges” will receive £2.9 billion. Of that amount, £800 million will go toward projects including chemistry and nanotechnology research, […]
As of the end of October, the US FDA had conducted 97 inspections of the more than 600 pharmaceutical plants in India registered with the US. It found that at many facilities producing medicines for export to the US, samples of drugs failing to meet quality standards for purity were retested rather than discarded. Failed […]
The Russian government’s goals for the sciences call for an update to the country’s scientific system. The goals are for R&D financing to make up 1.77% of GDP, Russian scientific publications to constitute at least 2.44% of the global total and the income of Russian scientists to be 200% that of the average in their […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
